Apimeds Pharmaceuticals US, Inc (APUS) Stock Score, Valuation & Financial Research

Apimeds Pharmaceuticals US, Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for APUS

Apimeds Pharmaceuticals US, Inc does not currently have a complete Wall Street Score. The stored market price is USD 5.00. These figures are a research snapshot, not a buy or sell recommendation.

What Apimeds Pharmaceuticals US, Inc does

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. The company funds its operations and clinical development activities primarily through the issuance of equity securities and support from its parent company and strategic partners.

Products and services

  • The company is developing Apitox, a purified bee venom-based therapeutic candidate intended for the treatment of knee osteoarthritis and multiple sclerosis, which is currently in the clinical trial stage and has not received FDA approval.

Brands and product families

  • Apitox — Purified bee venom-based therapeutic candidate for knee osteoarthritis and multiple sclerosis. Source

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations — The company utilizes unnamed third-party contract research organizations to conduct clinical trials and manage regulatory development processes. Source

Business relationships and partnerships

  • Apimeds Inc. (Korea) — A strategic partner and affiliate that provides access to clinical data and development opportunities for the Apitox therapeutic candidate. Source
  • Inscobee Inc. — The parent company of Apimeds Korea which holds a controlling interest in Apimeds Pharmaceuticals US, Inc. and provides strategic support. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — Various companies developing treatments for osteoarthritis and multiple sclerosis that compete for clinical success and market share. Source

Business strengths to evaluate

  • Access to clinical data and development history from Apimeds Korea Source

Business risks and research considerations

  • Lack of revenue and history of operating losses Source
  • Dependence on FDA approval for Apitox Source
  • Reliance on strategic partners and parent company funding Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

APUS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.00
Market capitalization:
7.55M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -58.17M
Free cash flow:
USD -8.98M
Cash:
USD 278.37K
Total debt:
USD 14.58M
EPS:
USD -49.29

What stands out

  • Free cash flow is USD -8.98M, negative for the stored period.
  • The balance sheet shows USD 278.37K of cash versus USD 14.58M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 14.3M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for APUS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can APUS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is APUS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for APUS to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of APUS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research APUS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.